Lambert-Eaton Myasthenic Syndrome (LES)

The Herald | HeraldOnline.com Catalyst Announces Initiation of an Expanded Access Program to Provide Firdapse at No Cost to   ... CORAL GABLES, Fla., Apr 23, 2014 (BUSINESS WIRE) -- Catalyst Pharmaceutical Partners, Inc. announced today it has begun the process required to establish an expanded access program (EAP) to make available in the United States its investigational potassium channel inhibitor, Firdapse™ (amifampridine phosphate or 3,4-DAP phosphate), to patients diagnosed with  Lambert-Eaton Myasthenic Syndrome (LEMS)  through their neuromuscular disease specialists. The product, currently in Phase 3 development, will be provided at no cost until sometime after approval. Program enrollment will begin in the next few months, pending FDA review and approvals. “As part of our ongoing commitment to the LEMS community, we are making Firdapse available to those who would like access to this investigational drug, but are unable to participate in clinical studies or tra

The Shuman Law Firm Investigates Catalyst Pharmaceutical Partners, Inc. BOULDER, Colo., May 15, 2014 (BUSINESS WIRE) --  The Shuman Law Firm  announces that it is investigating potential claims against certain officers and directors of Catalyst Pharmaceutical Partners, Inc. (“Catalyst” or the “Company”) (Nasdaq:  CPRX  ). Catalyst is as a Florida-based development-stage specialty pharmaceutical company. Catalyst’s major product is Firdapse which is used to treat Lambert-Eaton Myasthenic Syndrome (“LEMS”). The Firm’s investigation relates to allegations raised in a class action lawsuit against the Company relating to its disclosures regarding Firdapse and LEMS. The class action complaint alleges that the Company’s senior officers and/or directors mislead investors by (i) concealing that a competitor has been providing patients for free with a drug that is nearly biologically equivalent to the drug for which Catalyst seeks  Food and Drug Administration  (“FDA”) approval; (ii) overst

NEWS